Electroconvulsive therapy and FDA adverse reporting – our findings and future goals
This spring, Life After ECT launched a comprehensive FDA reporting guide for injured electroconvulsive therapy (ECT) recipients. This post is a progress update and an overview of our future reporting goals.
0 Comments
October 12, 2022